The Food and Drug Administration Safety and Innovation Act (FDASIA), signed into law on July 9, 2012, expands the FDA’s authorities and strengthens the agency’s ability to safeguard and advance public health by:
- Giving the authority to collect user fees from industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biological products.
- Promoting innovation to speed patient access to safe and effective products.
- Increasing stakeholder involvement in FDA processes.
- Enhancing the safety of the drug supply chain.